Literature DB >> 17587207

Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer.

Vladimir Mouraviev1, Janice M Mayes, Leon Sun, John F Madden, Judd W Moul, Thomas J Polascik.   

Abstract

BACKGROUND: Early detection of small-volume prostate cancer (PCa) has led to the concept of focal therapy to treat PCa as an organ-sparing, minimally invasive procedure. The authors sought to determine the frequency of unilateral cancers in the contemporary prostate-specific antigen (PSA) era to determine the percentage of patients who would be candidates for hemiablation of the prostate by using focal therapy while preserving the contralateral lobe.
METHODS: Paraffin-embedded radical prostatectomy specimens (1184 specimens) from consecutive patients between 2002 and 2006 with pathologic organ confined PCa were analyzed. Pathologic assessment focused on tumor laterality and percentage of tumor involvement (PTI) along with other routine parameters such as pathological T-classification (pT), pathological Gleason Score (pGS), extracapsular extension (ECE), and surgical margins (SM). Clinical and pathologic parameters were analyzed by univariate and multivariate methods.
RESULTS: Completely unilateral cancers were identified in 227 (19.2%) of 1184 patients. Of these patients, 164 (72.2%) had PTI of < or =5%, 40 (17.6%) had a PTI of 5.01%-10%, 9 (4.0%) had a PTI of 10.01%-15%, and 14 (6.2%) had a PTI of > 15%, respectively (P < .0005). African-American men had bilateral cancers more commonly that non-African-American men, eg, 90.8% versus 79.2%, respectively (P < .0005). Race, PTI, pGS, and SM were independent predictors by multivariate logistic regression (P < or = .05).
CONCLUSIONS: This study suggests that 1 in 5 men diagnosed with PCa have small volume, completely unilateral cancers that may be amenable to hemiablation of the prostate. Further study is needed to develop predictive models to select candidates for focal therapy.

Entities:  

Mesh:

Year:  2007        PMID: 17587207     DOI: 10.1002/cncr.22858

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  26 in total

Review 1.  Robotic prostate biopsy and its relevance to focal therapy of prostate cancer.

Authors:  Henry Ho; John S P Yuen; Christopher W S Cheng
Journal:  Nat Rev Urol       Date:  2011-09-20       Impact factor: 14.432

Review 2.  Focal cryotherapy for prostate cancer.

Authors:  Matvey Tsivian; Thomas J Polascik
Journal:  Curr Urol Rep       Date:  2010-05       Impact factor: 3.092

3.  Focal therapy: a new paradigm for the treatment of prostate cancer.

Authors:  Basir Tareen; Guilherme Godoy; Samir S Taneja
Journal:  Rev Urol       Date:  2009

4.  There is no role for focal therapy in prostate cancer.

Authors:  Peter Black
Journal:  Can Urol Assoc J       Date:  2009-08       Impact factor: 1.862

Review 5.  [Focal therapy for prostate cancer].

Authors:  M Schostak
Journal:  Urologe A       Date:  2019-05       Impact factor: 0.639

6.  Updated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: implications for focal therapy.

Authors:  Paul L Nguyen; Ming-Hui Chen; Yuanye Zhang; Clare M Tempany; Robert A Cormack; Clair J Beard; Mark D Hurwitz; W Warren Suh; Anthony V D'Amico
Journal:  J Urol       Date:  2012-08-15       Impact factor: 7.450

7.  Recent advances in focal therapy of prostate and kidney cancer.

Authors:  Matvey Tsivian; Thomas J Polascik
Journal:  F1000 Med Rep       Date:  2010-01-18

Review 8.  Pathologic basis of focal therapy for early-stage prostate cancer.

Authors:  Vladimir Mouraviev; Janice M Mayes; Thomas J Polascik
Journal:  Nat Rev Urol       Date:  2009-04       Impact factor: 14.432

9.  Parameters predicting postoperative unilateral disease in patients with unilateral prostate cancer in diagnostic biopsy: a rationale for selecting hemiablative focal therapy candidates.

Authors:  Stavros Sfoungaristos; Petros Perimenis
Journal:  Can Urol Assoc J       Date:  2013 Jan-Feb       Impact factor: 1.862

Review 10.  Active surveillance and radical therapy in prostate cancer: can focal therapy offer the middle way?

Authors:  Hashim Uddin Ahmed; Mark Emberton
Journal:  World J Urol       Date:  2008-08-14       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.